封面
市场调查报告书
商品编码
1410912

下一代定序市场:市场规模(按细分市场)、份额、监管、报销、预测(~2033 年)

Next Generation Sequencers Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

出版日期: | 出版商: GlobalData | 英文 | 订单完成后即时交付

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

新一代定序可以透过 DNA 片段化并以自动并行方式对这些片段进行定序来一次对整个基因组进行定序。新一代定序仪可用于全基因组定序、外显子定序、转录组定序(RNA 定序)和多基因组的标靶定序。

测试大量突变以製定个人化治疗策略现在已成为常态,并且越来越多地使用下一代定序来评估肿瘤活检中各种潜在的可靶向突变。

该报告深入探讨了全球下一代定序仪市场,包括竞争格局、SWOT 分析、到 2033 年的市场预测、COVID-19 的影响以及区域和国家趋势。

目录

目前市面上的下一代定序仪及竞争状况

  • 洞察关键产业趋势
  • 2015年至2033年按细分市场划分的下一代定序仪市场总收入及市场前景
  • 有关数量、平均售价和市场价值的详细数据

全球、区域和国家见解

  • 下一代定序仪市场的SWOT分析
  • 下一代定序市场的竞争动态洞察与趋势
  • 按国家/地区划分的医疗保健系统概览
  • 各国报销政策
  • 各国医疗技术法规现状

Abstract

Next Generation Sequencers Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Next Generation Sequencers market for the year 2020 and beyond. Next Generation Sequencers allows an entire genome to be sequenced at once by fragmenting DNA and sequencing those fragments in an automated, parallel manner. Next Generation Sequencers can be used for whole-genome sequencing, exome sequencing, transcriptome sequencing (RNA sequencing), and targeted sequencing of multigene panels.

It is now standard to test for a high number of mutations to personalize treatment decisions, use of Next Generation Sequencers that can evaluate tumor biopsies for a wide range of potentially targetable mutations is increasing.

This model includes High-throughput Next Generation Sequencers, Medium-throughput Next Generation Sequencers, Low-throughput Next Generation Sequencers.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Next Generation Sequencers and evolving competitive landscape:

  • Insightful review of the key industry trends.
  • Annualized total Next Generation Sequencers market revenue by segment and market outlooks from

2015- 2033

  • Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Next Generation Sequencers market.
  • Competitive dynamics insights and trends provided for Next Generation Sequencers market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Illumina Inc, Pacific Biosciences, Thermo Fisher Scientific Inc, Singular Genomics System Inc , and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

  • CMO executives who must have deep understanding of the Next Generation Sequencing (NGS) Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

  • Understand the impact of COVID-19 on Next Generation Sequencing (NGS) Tests market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Next Generation Sequencing (NGS) Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Next Generation Sequencing (NGS) Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Next Generation Sequencing (NGS) Tests market from 2015-2033.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable